MTOR and nonpapillary renal cell carcinoma: To guide the development of clinical treatment strategies, we screened tyrosine kinase inhibitors, mTOR inhibitors, and histone deacetylase (HDAC) inhibitors from the pRRophetic package to assess their association with ccRCC resistance.